Literature DB >> 16955251

Role of hospital stay and antibiotic use on Pseudomonas aeruginosa gastrointestinal colonization in hospitalized patients.

D Lepelletier1, N Caroff, D Riochet, P Bizouarn, A Bourdeau, F Le Gallou, E Espaze, A Reynaud, H Richet.   

Abstract

The prospective cohort study presented here assessed the risk factors associated with Pseudomonas aeruginosa gastrointestinal colonization (PAGIC) in 933 patients hospitalized in five different wards in a French university hospital. A total of 195 patients were colonized. By logistic regression, hospitalization in an intensive care unit and length of hospital stay were independent risk factors. A significant association was observed between fluoroquinolone use and PAGIC caused by an ofloxacin-resistant strain (p < 0.0001), imipenem use and PAGIC caused by an imipenem-resistant strain (p < 0.0002) and ceftazidime use and PAGIC caused by a ceftazidime-resistant strain (p < 0.02). The ecological impact of antibiotic use is of great clinical relevance and clinicians should consider antimicrobial resistance in order to limit the development and dissemination of resistant microorganisms.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16955251     DOI： 10.1007/s10096-006-0184-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  15 in total

1.  Action against antibiotic resistance: no time to lose.

Authors:  P M Hawkey
Journal:  Lancet       Date:  1998-05-02       Impact factor: 79.321

2.  How many nosocomial infections are associated with cross-transmission? A prospective cohort study in a surgical intensive care unit.

Authors:  Klaus Weist; Kathrin Pollege; Ines Schulz; Henning Rüden; Petra Gastmeier
Journal:  Infect Control Hosp Epidemiol       Date:  2002-03       Impact factor: 3.254

3.  Epidemiological studies of Pseudomonas species in patients with leukemia.

Authors:  G P Bodey
Journal:  Am J Med Sci       Date:  1970-08       Impact factor: 2.378

4.  Endemicity, molecular diversity and colonisation routes of Pseudomonas aeruginosa in intensive care units.

Authors:  X Bertrand; M Thouverez; D Talon; A Boillot; G Capellier; C Floriot; J P Hélias
Journal:  Intensive Care Med       Date:  2001-08       Impact factor: 17.440

5.  Frequency and molecular diversity of Pseudomonas aeruginosa upon admission and during hospitalization: a prospective epidemiologic study.

Authors:  Dominique S. Blanc; Christiane Petignat; Béatrice Janin; Jacques Bille; Patrick Francioli
Journal:  Clin Microbiol Infect       Date:  1998-05       Impact factor: 8.067

6.  Hospital-acquired pneumonia in critically ill patients: factors associated with episodes due to imipenem-resistant organisms.

Authors:  O Leroy; T d'Escrivan; P Devos; L Dubreuil; E Kipnis; H Georges
Journal:  Infection       Date:  2005-06       Impact factor: 3.553

7.  Colonization and resistance dynamics of gram-negative bacteria in patients during and after hospitalization.

Authors:  P Margreet G Filius; Inge C Gyssens; Irma M Kershof; Patty J E Roovers; Alewijn Ott; Arnold G Vulto; Henri A Verbrugh; Hubert P Endtz
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

8.  Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients.

Authors:  A P Zavascki; R P Cruz; L Z Goldani
Journal:  J Hosp Infect       Date:  2005-02       Impact factor: 3.926

9.  Effect of beta-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa.

Authors:  H Carsenti-Etesse; J D Cavallo; P M Roger; I Ziha-Zarifi; P Plesiat; E Garrabe; P Dellamonica
Journal:  Chirurgia (Bucur)       Date:  2002 Mar-Apr

10.  Oropharyngeal and fecal carriage of Pseudomonas aeruginosa in hospital patients.

Authors:  S K Murthy; A L Baltch; R P Smith; E K Desjardin; M C Hammer; J V Conroy; P B Michelsen
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948
View more
  6 in total

1.  Risk factors for development of intestinal colonization with imipenem-resistant Pseudomonas aeruginosa in the intensive care unit setting.

Authors:  Anthony D Harris; J Kristie Johnson; Kerri A Thom; Daniel J Morgan; Jessina C McGregor; Adebola O Ajao; Anita C Moore; Angela C Comer; Jon P Furuno
Journal:  Infect Control Hosp Epidemiol       Date:  2011-07       Impact factor: 3.254

2.  Duration of hospital admission and the need for empirical antipseudomonal therapy.

Authors:  N Daneman; M Elligsen; S A N Walker; A Simor
Journal:  J Clin Microbiol       Date:  2012-06-06       Impact factor: 5.948

3.  Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients.

Authors:  José A Martínez; Esther Delgado; Sara Martí; Francesc Marco; Jordi Vila; Josep Mensa; Antoni Torres; Carles Codina; Antoni Trilla; Alex Soriano; Aitor Alquezar; Pedro Castro; José M Nicolás
Journal:  Intensive Care Med       Date:  2008-10-21       Impact factor: 17.440

4.  The ecology of antibiotic use in the ICU: homogeneous prescribing of cefepime but not tazocin selects for antibiotic resistant infection.

Authors:  Andrew N Ginn; Agnieszka M Wiklendt; Heather F Gidding; Narelle George; James S O'Driscoll; Sally R Partridge; Brian I O'Toole; Rita A Perri; Joan Faoagali; John E Gallagher; Jeffrey Lipman; Jonathan R Iredell
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

5.  Empiric Usage of "Anti-Pseudomonal" Agents for Hospital-Acquired Urinary Tract Infections.

Authors:  Ori Rahat; Murad Shihab; Elhai Etedgi; Debby Ben-David; Inna Estrin; Lili Goldshtein; Shani Zilberman-Itskovich; Dror Marchaim
Journal:  Antibiotics (Basel)       Date:  2022-07-04

6.  Incidence and risk factors for surgical site infection in general surgeries.

Authors:  Rafael Lima Rodrigues de Carvalho; Camila Cláudia Campos; Lúcia Maciel de Castro Franco; Adelaide De Mattia Rocha; Flávia Falci Ercole
Journal:  Rev Lat Am Enfermagem       Date:  2017-12-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.